Business
enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events
57 patients enrolled to date in the SAVVE® studyFull SAVVE enrollment expected by year-endJuly 13 - Company to participate in investor event to further
About this update from Envveno Medical Corporation
[{"type":"text","content":"57 patients enrolled to date in the SAVVE® studyFull SAVVE enrollment expected by year-endJuly 13 - Company to participate in investor event to further discuss enrollmentJuly 18 - KOL event with two SAVVE study Principal InvestigatorsIRVINE, CA / ACCESSWIRE / July 5, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) (\"enVVeno\" or the \"Company\"), a company setting new standards of care for the treatment of venous disease, today provided an update on enrollment for its ongoing SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) U.S. pivotal study for the VenoValve and announced two upcoming investor events (details below). The SAVVE pivotal study is a prospective, non-blinded, single arm, multi-center study of 75 CVI patients. To date, the Company has enrolled 57 patients in the study and expects enrollment to be completed before the end of 2023.\"We are very encouraged by the enrollment momentum we have created over the past few months, including the number of new patients currently being considered for SAVVE, and are confident that we will reach full enrollment by the end of the year,\" commented Robert Berman, CEO of enVVeno Medical. \"The new patient enrollment initiatives that we implemented over the course of the study have resulted in significant progress in what is still a somewhat unpredictable and challenging hospital environment.\"Investor Event: Virtual Investor Summer Spotlight SeriesThe Company will be participating in the Virtual Investor Summer Spotlight Series on Thursday, July 13, 2023 at 12:00 PM ET, sharing additional information about SAVVE enrollment and the initiatives implemented by enVVeno Medical. The format will feature a one-on-one question and answer session and investors will have the opportunity to submit questions. To participate in the event, a live video webcast link will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.KOL Event: \"VenoValve® - A New Potential Treatment Paradigm for Vascular Disease\"On July 18, 2023, at 3:00 PM ET, the Company will host a KOL event featuring two Principal Investigators from its ongoing VenoValve U.S. pivotal trial; Dr. David Dexter, Sentara Healthcare, Associate Professor Surgery, Eastern Virginia Medical School and D...